Literature DB >> 17332288

Virus-associated tumor imaging by induction of viral gene expression.

De-Xue Fu1, Yvette C Tanhehco, Jianmeng Chen, Catherine A Foss, James J Fox, Victor Lemas, Ja-Mun Chong, Richard F Ambinder, Martin G Pomper.   

Abstract

PURPOSE: EBV and other herpesviruses are associated with a variety of malignancies. The EBV thymidine kinase (TK) is either not expressed or is expressed at very low levels in EBV-associated tumors. However, EBV-TK expression can be induced in vitro with several chemotherapeutic agents that promote viral lytic induction. The goal of this study is to image EBV-associated tumors by induction of viral TK expression with radiolabeled 2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabinofuranoside (FIAU). EXPERIMENTAL
DESIGN: Immunoblot, luciferase reporter assay, and in vitro assay with [(14)C]FIAU were used to show the effects of bortezomib on the induction of lytic gene expression of EBV-associated tumor cells. In vivo imaging and ex vivo biodistribution studies with [(125)I]FIAU on EBV-associated tumors were done to visualize and confirm, respectively, the EBV(+) tumor-specific effects of bortezomib.
RESULTS: In vitro assays with [(14)C]FIAU and ex vivo biodistribution studies with [(125)I]FIAU showed that uptake and retention of radiolabeled FIAU was specific for cells that express EBV-TK. Planar gamma imaging of EBV(+) Burkitt's lymphoma xenografts in severe combined immunodeficient mice showed [(125)I]FIAU localization within tumors following treatment with bortezomib.
CONCLUSIONS: These results indicate the feasibility of imaging chemotherapy-mediated viral lytic induction by radiopharmaceutical-based techniques such as single photon emission computed tomography and positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332288     DOI: 10.1158/1078-0432.CCR-06-2295

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.

Authors:  Chia Chi Sun; David A Thorley-Lawson
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

2.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Sébastien Baechler; De-Xue Fu; Caroline Esaias; Martin G Pomper; Richard F Ambinder; George Sgouros
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

3.  Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

Authors:  Erin G Reid; David Looney; Frank Maldarelli; Ariela Noy; David Henry; David Aboulafia; Juan Carlos Ramos; Joseph Sparano; Richard F Ambinder; Jeannette Lee; Ethel Cesarman; Sara Yahyaei; Ronald Mitsuyasu; William Wachsman
Journal:  Blood Adv       Date:  2018-12-26

4.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.

Authors:  Mark N Polizzotto; Corina Millo; Thomas S Uldrick; Karen Aleman; Millie Whatley; Kathleen M Wyvill; Deirdre O'Mahony; Vickie Marshall; Denise Whitby; Roberto Maass-Moreno; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  J Infect Dis       Date:  2015-03-31       Impact factor: 5.226

6.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Deirdre O'Mahony; Kathleen M Wyvill; Victoria Wang; Vickie Marshall; Stefania Pittaluga; Seth M Steinberg; Giovanna Tosato; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

7.  Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

Authors:  Courtney M Shirley; Jianmeng Chen; Meir Shamay; Huili Li; Cynthia A Zahnow; S Diane Hayward; Richard F Ambinder
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

8.  SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.

Authors:  Renfeng Li; Leyao Wang; Gangling Liao; Catherine M Guzzo; Michael J Matunis; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

Review 9.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 10.  Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.

Authors:  John Koreth; Edwin P Alyea; William J Murphy; Lisbeth A Welniak
Journal:  Biol Blood Marrow Transplant       Date:  2009-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.